ATRC (AtriCure) Moat Score: 5/10 (As of Jun. 27, 2026)


ATRC AtriCure Inc ATRC
78 GF Score
Price $30.12
GF Value $39.75
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AtriCure Moat Score?

AtriCure ATRC +7.29% 78 Moat Score is 5 as of Jun. 27, 2026. GuruFocus rates ATRC with a GF Score™ of 78/100 and a GF Value™ of $39.75 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 846 Medical Devices & Instruments companies, AtriCure ranks better than 91.13% on this metric.

AtriCure has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

AtriCure has Narrow Moat: AtriCure Inc has a solid narrow moat due to its proprietary technology and regulatory approvals in the medical device industry. It benefits from customer switching costs and a strong distribution network, but lacks the scale and brand strength to be considered a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AtriCure might have Narrow Moat - Solid narrow moat.

AtriCure  (NAS:ATRC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AtriCure Moat Score Related Terms

ATRC vs STAA, NNNN, KMTS: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, AtriCure's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AtriCure Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Moat Score distribution charts can be found below:

* The bar in red indicates where AtriCure's Moat Score falls into.


ATRC
78GF Score
AtriCure Inc ATRC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
AtriCure (ATRC) has a Moat Score of 5 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, AtriCure ranks #75 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is AtriCure's Moat Score too high?
AtriCure's current Moat Score is 5. Based on the distribution chart, AtriCure ranks #75 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AtriCure has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Moat Score compare to STAA and NNNN?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #75 out of 846 companies for Moat Score. This places AtriCure in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. AtriCure's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.75, compared to a current price of $30.12 — trading 24.2% below its estimated fair value. The current Moat Score is 5. AtriCure's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For AtriCure (ATRC), the current Moat Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtriCure (ATRC) Overvalued in 2026?

Based on GuruFocus' analysis, AtriCure stock appears to be undervalued. The current stock price of $30.12 is trading 24.2% below its estimated GF Value™ of $39.75. GuruFocus considers AtriCure to be Modestly Undervalued.

Key valuation signals for ATRC:

  • Moat Score: 5
  • GF Value™: $39.75 vs. price of $30.12 (24.2% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtriCure Business Description

Address 7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
78GF Score

Get the complete analysis for ATRC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.12
Price
$39.75
GF Value